“The notion that we have to see a patient in front of us every time in order to have a billable encounter is antiquated,” says Gary Kirsh, MD.
In an interview at the 2021 LUGPA Annual Meeting, Gary Kirsh, MD, chair, LUGPA Political Affairs Committee and president, The Urology Group, discussed the latest developments in telehealth reimbursement for urologists.
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.